Humacyte Inc.
Organization details
- Legal name
- Humacyte Inc.
- Former names
- Alpha Healthcare Acquisition Corp.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Durham
- Headquarters state / province
- North Carolina
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- HUMA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001818382
- EIN
- 85-1763759
Board of directors
-
Brady W. Dougan · DirectorSince 2023
-
Charles Bruce Green · DirectorSince 2023
-
D. Scott Coward · DirectorSince 2026
-
Diane Seimetz · DirectorSince 2023
-
Emery N. Brown · DirectorSince 2023
-
Gordon M. Binder · DirectorSince 2023
-
John Philip Bamforth · DirectorSince 2024
-
Kathleen Sebelius · DirectorSince 2023
-
Keith Anthony Jones · DirectorSince 2024
-
Laura E. Niklason · Director · President, CEO and DirectorSince 2023
-
Max N. Wallace · DirectorSince 2023
-
Michael T. Constantino · DirectorSince 2023
-
Paul Brian Kuznik · DirectorSince 2026
-
Rajiv Shukla · DirectorSince 2023
-
Susan Richards Windham-Bannister · DirectorSince 2023
-
Todd Pope · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
77.6%
-
84.7%
-
84.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $89,990
- 5 purchases by 3 insiders
- Sold, last 12 months
- $82,597
- 2 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 14, 2026 | Keith Anthony Jones Director | Open-market purchase | +10,000 | $0.56 | $5,600 |
| Aug 20, 2026 | Keith Anthony Jones Director | Open-market purchase | +10,000 | $0.69 | $6,900 |
| Aug 17, 2026 | Keith Anthony Jones Director | Open-market purchase | +30,000 | $0.59 | $17,700 |
| May 19, 2026 | Kathleen Sebelius Director | Open-market purchase | +56,818 | $0.88 | $50,000 |
| May 18, 2026 | Michael T. Constantino Director | Open-market purchase | +11,000 | $0.89 | $9,790 |
| May 18, 2026 | Sander Dale A. Officer (CFO and Chief Corp. Dev. Off) | Open-market sale | −45,887 | $0.90 | $41,298 |
| May 18, 2026 | Parikh Shamik J Officer (Chief Medical Officer) | Open-market sale | −45,887 | $0.90 | $41,298 |
| Nov 16, 2025 | Sander Dale A. Officer (CFO and Chief Corp. Deve. Off.) | Grant or award | +311,100 | — | — |
| Nov 16, 2025 | Parikh Shamik J Officer (Chief Medical Officer) | Grant or award | +311,100 | — | — |
| Aug 20, 2025 | Brady W. Dougan Director | Open-market sale | −591,685 | $1.58 | $934,862 |
| Aug 20, 2025 | Laura E. Niklason Director, Officer (President, CEO and Director) | Open-market sale | −591,685 | $1.58 | $934,862 |
| Aug 19, 2025 | Brady W. Dougan Director | Open-market sale | −1,100,000 | $1.63 | $1,793,000 |
| Aug 19, 2025 | Laura E. Niklason Director, Officer (President, CEO and Director) | Open-market sale | −1,100,000 | $1.63 | $1,793,000 |
| Aug 18, 2025 | Brady W. Dougan Director | Open-market sale | −549,360 | $1.83 | $1,005,329 |
| Aug 18, 2025 | Laura E. Niklason Director, Officer (President, CEO and Director) | Open-market sale | −549,360 | $1.83 | $1,005,329 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Humacyte Inc.
Who is the CEO of Humacyte Inc.?
Laura E. Niklason is Humacyte Inc.'s President, CEO and Director.
How many directors are on Humacyte Inc.'s board?
Humacyte Inc.'s board has 16 directors: Brady W. Dougan, Charles Bruce Green, D. Scott Coward, Diane Seimetz, Emery N. Brown, Gordon M. Binder, John Philip Bamforth, Kathleen Sebelius, Keith Anthony Jones, Laura E. Niklason and 6 others.
Are Humacyte Inc. insiders buying or selling shares?
Over the last 12 months, Humacyte Inc. insiders bought $89,990 of shares in 5 purchases and sold $82,597 of shares in 2 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="humacyte-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.